 Vaccination prevention CAPD staphylococcal infection results prospective multicentre clinical trial stable CAPD patients Australian New Zealand centers blinded fashion groups effect vaccination commercial preparations combined staphylococcus toxoid whole staphylococci SB normal saline solution SS incidence peritonitis exit site infection nasal carriage prospective period addition levels IgG IgA IgM trial period serum dialysate serum levels anti-alpha hemolysin dialysate levels fibronectin specific antistaphylococcal antibodies period treatment SB SS incidence peritonitis catheter-related infection nasal carriage vaccination SB significant increase level serum anti-alpha hemolysin month duration study level increase unrelated subsequent rate peritonitis Vaccination SB SS significant increase dialysate level specific antibodies aureus Serum levels IgG IgA IgM complement normal range CAPD patients vaccination SB addition dialysate levels IgG IgA IgM complement times serum levels vaccination summary immunisation anti-staphylococcal agent successful peritonitis exit site infection CAPD patients